A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%
The treatment is still experimental, but results from Moderna and Merck add scientific support for a vaccine-based approach to treating the cancer.
22 Oct 23:54 · TIME
Personalised mRNA Cancer Vaccine Cuts Melanoma Recurrence
Moderna and Merck report that their personalised mRNA cancer vaccine combined with Keytruda cuts melanoma recurrence or death risk by 42%.
22 Oct 22:28 · Greek City Times
last updated on 23 Oct 08:07